Built from Elanco Animal Health Incorporated’s own filings with the U.S. Securities and Exchange Commission (SEC). Figures are as reported, with per-share history restated onto today’s share basis. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.
ELAN · NYSE · Healthcare · Drug Manufacturers Specialty and Generic
$26.48-1.1%Nov 11 close
Figures through September 30, 2026, from the 10-Q filed November 6, 2026
Company outlook: revenue of $5.2B to $5.2B for Fiscal year 2026 — up 9.6% on a year earlier
The themes Elanco Animal Health is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
TAKTakeda Pharmaceutical Company Limited$33.5BA
NBIXNeurocrine Biosciences, Inc.$17.6BA+
KNSAKiniksa Pharmaceuticals International, plc$8.1BA+
LQDALiquidia Corporation$5BA
BHCBausch Health Companies Inc.$3.1BARose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher CorporationOct 21, 2026CBGraded C, now B
MCKMckesson CorporationNov 4, 2026BAGraded B, now A
CVSCVS Health CorpNov 4, 2026BAGraded B, now A
EWEdwards Lifesciences CorporationNov 4, 2026BAGraded B, now A
BIIBBiogen Inc.Oct 28, 2026BAGraded B, now AJust reported
From Elanco Animal Health's results release of November 6, 2026; its quarterly report has since been filed.
Actual
$1.27B
+11% y/y
-7.5% q/q
Guided
—
No guide given
Actual
$0.27
Guided
$0.19
midpoint
EPS, GAAP: $0.04
Q4 2026
Full year 2026
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Grade A
The band under the price shows the grade on each date, built only from filings that were public by then.
Showing 2 of 32 quarters of Elanco Animal Health Incorporated’s grade history. The other 30 go back to February 2019.